18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study
18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study in Patients With Various Cancers
First Affiliated Hospital of Fujian Medical University
5 participants
Jun 25, 2024
INTERVENTIONAL
Conditions
Summary
As a new dual targeting PET radiotracer, 18F-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 18F-FAPI-Biotin in patients with various types of cancer and compared them with the results of 18F-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 18F-FAPI.
Eligibility
Inclusion Criteria1
- Various solid tumors with available histopathological findings • Signed informed consent
Exclusion Criteria1
- pregnant or lactational women • who suffered from severe hepatic and renal insufficiency
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The dose will be 148-296 MBq given intravenously.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06734572